Making the price tag more justifiable.
https://newsroom.csl.com/2025-02-07-CSL-Behrings-Gene-Therapy-HEMGENIX-R-etranacogene-dezaparvovec-drlb-Four-Years-Post-Infusion-Data-Continue-to-Show-Sustained-Efficacy-and-Safety-in-Adults-with-Hemophilia-B
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$260.88 |
Change
-4.650(1.75%) |
Mkt cap ! $126.3B | |||
| Open | High | Low | Value | Volume |
| $263.90 | $265.00 | $260.88 | $240.8M | 916.2K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 69 | $260.86 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $261.00 | 1249 | 1 |
View Market Depth
| Last trade - 16.10pm 08/08/2025 (20 minute delay) ? |
| CSL (ASX) Chart |